Cue Biopharma has been initiated with a Buy rating following positive phase 2 trial results for its drug CUE-221 in treating chronic spontaneous urticaria (CSU). The drug demonstrated a novel dual mechanism of action and outperformed XOLAIR, with 54% of patients achieving complete hive resolution at 12 weeks. Upcoming milestones include 36-week pharmacokinetic and IgE data expected in 2026, as well as planned global phase 2b/3 studies targeting CSU and food allergy markets. Despite a recent $50 million financing, the company has a cash runway of only 12 months, indicating a need for further capital raises amid competitive risks.
Cue Biopharma's recent phase 2 trial success comes as 56 of 94 priced Health-sector US stocks on Pluang rose today. For readers following the Health sector, here is Pluang's market snapshot as of Sep 22, 2026 03:42 WIB: Enveric Biosciences Inc (ENVB) traded at USD 1.56 with a 3.70% decline and 100% sell order activity, Agilent Technologies Inc (A) rose 3.58% to USD 162.07, and Recursion Pharmaceuticals Inc (RXRX) increased 3.39% to USD 3.96 with 59% buy order activity and a typical hold time of 22 days.
Two directors of Equitable Holdings sold shares recently, with Bertram L. Scott selling 2,780 shares and Craig C. MacKay selling 2,000 shares. Meanwhile, institutional investors showed mixed activity: Engineers Gate Manager LP drastically cut its hol...
Shares of Greenland-linked mining companies surged following a new U.S.-Denmark-Greenland security agreement that boosted investor interest in Greenland's mineral resources. Greenland Mines Ltd. jumped over 229%, while Critical Metals Corp. rose near...
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
Novo Nordisk held its Analyst/Investor Day on September 21, 2026, featuring presentations from its top executives including the CEO and heads of R&D, product strategy, and operations. The event focused on the company's future plans, product pipeline,...
In Germany, swapping Bitcoin for gold is treated as a taxable sale unless the Bitcoin was held for over a year or total private sale gains are under €1,000 annually. The tax treatment varies depending on the form of gold acquired—physical bars, gold ...
